Perrigo Company PLC says the recent sale of its UK-based Rosemont Pharmaceuticals liquid generics business “proves” that attractive multiples are still out there in the generics space but it “will take some time” yet to complete the planned separation of its US Prescription Pharmaceuticals business, given the continued poor value Perrigo sees.
There had been “no change” in Perrigo’s progress, president and CEO Murray Kessler told investors during the company’s second-quarter earnings call, as he reflected on Perrigo’s overarching strategy to complete a transaction for its Prescription